A major update appears in the Boxed Warning, the most prominent safety warning required by the FDA. The warning now ...

"All healthcare providers should be aware of the risks of DPD deficiency," inform patients of toxicity risks, and test patients unless treatment is immediately needed, the agency said.

Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.

The clinical description of severe toxicity fails to capture the suffering, shock, and tragedy experienced by our loved ones who were fatally overdosed after not being offered this important and ...

Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says the Committee for ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...